more informationMore information: Computer Curation of Patents & Scientific Literature by Dr. Stephen Boyer of IBM Research | Molecular Curation of the Scientific Literature
Stephen Kane Boyer is a researcher in the interdisciplinary space of chemistry and computer science. He pioneered the use of computers to automatically curate scientific literature and patents, expanding for the scientific community their understanding and utility of published information in medicine, the physical sciences and intellectual property.
Dr. Boyer’s early work as a synthetic chemist in the pharmaceutical sector provided the foundation for his insight into molecular structure–property correlations, particularly in the field of health and life sciences. His best-known commercialized pharmaceutical syntheses include drugs for the treatment of infection and cardiovascular disease. At Ciba-Geigy in Switzerland, he led the team that developed a commercial synthesis for Cefroxadine, an oral cephalosporin antibiotic, and contributed to the commercial synthesis of Benazepril, an angiotensin converting enzyme (ACE) inhibitor for the treatment of hypertension. His hands-on familiarity with creating molecules for bioactivity motivated his subsequent work in the creation of accessible and cross reference-able molecular databases.
Acknowledged as an influential leader in facilitating access to scientific information and patents, Dr. Boyer was instrumental in launching one of the world’s first public patent websites: the IBM Patent Server (now Delphion of Thomson Reuters). This multi-year effort to aggregate world intellectual property into a single database freely available on the Internet was a revolutionary act in its time and resulted in one of the largest and most successful publicly available Internet sites. This pivotal event impacted both the scientific and intellectual property (IP) communities, and positioned Dr. Boyer as an advisor to the World Intellectual Property Organization (WIPO) for the creation of WIPO-Net, a United Nations initiative to openly provide IP resources to international communities inclusive of third-world countries. In this capacity he continues to lecture on technical issues and draft proposals for improving international access to intellectual property.
More recently, Dr. Boyer initiated a collaboration of pharmaceutical industry leaders and international governmental organizations to explore his vision of enhanced access and curation of scientific information. This collaboration has formed the basis of a new commercial offering for IBM and has resulted in a large and significant donation of molecular content (~ 2 million molecular structures) to the National Institutes of Health (NIH). The impact of providing this aggregation of molecular data to the public will be felt internationally in business, academic and technical sectors. Dr. Boyer combines ten years of experience in the pharmaceutical industry (Ciba-Geigy / Novartis) with 25 years working in numerous technical and management capacities at IBM. He has authored numerous publications and patents in the areas of new drug syntheses and text- and image-analytics. He holds a B.A. from Temple University in Philadelphia and a Ph.D. in synthetic organic chemistry from Tufts University.